Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $57.00
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective cut by equities research analysts at Wedbush from $67.00 to $57.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Wedbush’s price target suggests a potential upside of 19.97% from the stock’s current price. […]
More Stories
Comcast Co. (NASDAQ:CMCSA) Shares Acquired by Kingsview Wealth Management LLC
Kingsview Wealth Management LLC grew its position in Comcast Co. (NASDAQ:CMCSA – Free Report) by 3.9% during the third quarter,...
Waddell & Associates LLC Increases Stock Holdings in Exxon Mobil Co. (NYSE:XOM)
Waddell & Associates LLC boosted its stake in Exxon Mobil Co. (NYSE:XOM – Free Report) by 1.3% in the third...
Home Depot (NYSE:HD) Shares Up 1.4% – Still a Buy?
The Home Depot, Inc. (NYSE:HD – Get Free Report) rose 1.4% during mid-day trading on Thursday . The stock traded...
Costco Wholesale Co. (NASDAQ:COST) Shares Acquired by Nicolet Advisory Services LLC
Nicolet Advisory Services LLC lifted its stake in shares of Costco Wholesale Co. (NASDAQ:COST – Free Report) by 11.7% during...
Alesco Advisors LLC Makes New Investment in Walmart Inc. (NYSE:WMT)
Alesco Advisors LLC purchased a new stake in Walmart Inc. (NYSE:WMT – Free Report) in the third quarter, according to...
Icon Wealth Advisors LLC Has $1.14 Million Position in The Walt Disney Company (NYSE:DIS)
Icon Wealth Advisors LLC cut its holdings in The Walt Disney Company (NYSE:DIS – Free Report) by 34.8% during the...